ArticleCancer medicine2020
Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 41 citations in OpenAlex.
- GATA1 knockdown enhances CD8Journal of molecular histology · 2026Article
- Article
- Unraveling fibrinogen-like protein 1's role in immune regulation.Frontiers in immunology · 2026Review
- Association of Fibrinogen-Like Protein 1 with Metabolic Disorders and Pregnancy Outcomes: A Case-Control StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting.Experimental hematology & oncology · 2025Article
- Fibrinogen superfamily proteins: Key regulators in hepatic disorders.World journal of experimental medicine · 2025Review
- IL-6 promotes metastasis and EMT of non-small cell lung cancer cells by up-regulating FGL1 via STAT3 pathway.Translational cancer research · 2025Article
- Serotonin receptor 5-HTJournal for immunotherapy of cancer · 2025Article
- Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies.International journal of biological sciences · 2025Review
- LAG-3 : recent developments in combinational therapies in cancer.Cancer science · 2024Review
- FGL1 and FGL2: emerging regulators of liver health and disease.Biomarker research · 2024Review
- Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells.JCI insight · 2024Article
- Role of Fibrinogen-like Protein 1 in Tumor Recurrence Following Hepatectomy.Journal of clinical and translational hepatology · 2024Review
- Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.Journal of experimental & clinical cancer research : CR · 2024Review
- Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review.Frontiers in oncology · 2024Review
- Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer.Frontiers in immunology · 2024Review
- The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer.Nature communications · 2023Article
- Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.The Journal of clinical investigation · 2023Article
- Aspirin and immunotherapy: a Faustian bargain?The Journal of clinical investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited effective treatments and ranks as the second most lethal tumor. Immunotherapy has brought great hope for HCC treatment. Oxysophocarpine is a bioactive alkaloid which poses various pharmacological functions including neuroprotective, anti-virus, anti-convulsant, and anti-nociception. However, there is little systematic study of Oxysophocarpine against HCC and its underlying potential and mechanism combined with immunotherapy in HCC treatment remain poorly unknown. This study was aimed to investigate whether Oxysophocarpine can distinctly suppress HCC cells and sensitize the immunotherapy of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.